Heron Therapeutics — Corporate Update (March 2022)

4 slides from Heron Therapeutics's corporate update, Mar 25, 2022

Slide 1: ZYNRELEF's Significant Economic Benefit With Pass-Through Status
ZYNRELEF’s Significant Economic Benefit With Pass-Through Status March 25, 2022 Exhibit 99.2 Company Logo
Slide 2: The Outpatient Setting of Care Now Represents >70% of Target Surgeries
The Outpatient Setting of Care Now Represents >70% of Target Surgeries With Hospital Outpatient Approaching 60% SKU: stock keeping unit. HOPD: hospital outpatient department. 1. Breakdown of settings of care based on 2021 Lexis Nexis claims data ~14M High Value Market Procedures1 OVERALL TOTAL ZYNRE
Slide 3: ZYNRELEF is the Only Reimbursed Local Anesthetic in Hospital Outpatient
Effective April 1, 2022 - ZYNRELEF is separately reimbursed for Medicare patients in the HOPD under 3-year transitional pass-through status ZYNRELEF is the only local anesthetic with separate reimbursement in the HOPD With pass-through status, the economic benefits vs Exparel in 340B and HOPD more t
Slide 4: ZYNRELEF's Economic Benefits Significantly Lower Hospital Costs, While Improving the Standard of Care
ZYNRELEF’s Economic Benefits Significantly Lower Hospital Costs, While Improving the Standard of Care *Estimates Comparing WAC (or 340B) acquisition cost to published ASP reimbursement for Medicare patients to calculate NCR based on ZYNRELEF Q2’22 rate and Exparel Q1’22 rate. Medicare reimbursement